Table 2 Improving safety in solid tumor therapy
From: The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
Choice of antigen |
Restricted expression |
Cancer glycosylation |
Vector structure |
Combinatorial CAR |
Suicide gene (iCaspase9) |
Treatment design |
Regional versus systemic administration |
Escalation method |
Simple infusion versus lymphodepletion |
Evaluate toxicities for management |
